Literature DB >> 15361843

Differential hypermethylation of SOCS genes in ovarian and breast carcinomas.

Kate D Sutherland1, Geoffrey J Lindeman, David Y H Choong, Sergio Wittlin, Luci Brentzell, Wayne Phillips, Ian G Campbell, Jane E Visvader.   

Abstract

Suppressor of cytokine signaling (SOCS) proteins have emerged as critical attenuators of cytokine-mediated processes, suggesting a role in the suppression of tumorigenesis. In the ovary and mammary gland, cytokines such as prolactin and IL-6 are important regulators of growth and differentiation. We have investigated whether silencing or inactivation of SOCS genes occurs in ovarian and breast carcinomas. The SOCS1 and SOCS2 CpG islands were found to be hypermethylated in 23 and 14% of primary ovarian cancers, respectively, whereas only SOCS1 was methylated in breast cancers (9%). Methylation of these genes did not occur in normal tissues. No correlation was apparent between methylation and loss of heterozygosity, and no somatic mutations were found in a large panel of carcinomas. Aberrant methylation of these SOCS genes correlated with transcriptional silencing in ovarian and breast cancer cell lines, since expression was induced by the demethylating agent 5-azadeoxycytidine. SOCS3 was not hypermethylated in either cancer type. Consistent with this data, SOCS1 and SOCS2 but not SOCS3 suppressed the growth of ovarian and breast cancer cells. Hypermethylation and silencing of specific SOCS genes in the ovary, and to a lesser extent in breast, may augment cytokine responsiveness in these tissues, thereby contributing to oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15361843     DOI: 10.1038/sj.onc.1207787

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  94 in total

1.  Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation.

Authors:  John C Cooper; Mingjian Shi; Fu-Yu Chueh; Srividya Venkitachalam; Chao-Lan Yu
Journal:  Int J Oncol       Date:  2010-05       Impact factor: 5.650

Review 2.  Negative regulation of cytokine signaling.

Authors:  Akihiko Yoshimura
Journal:  Clin Rev Allergy Immunol       Date:  2005-06       Impact factor: 8.667

3.  Suppressor of cytokine signaling-2 gene disruption promotes Apc(Min/+) tumorigenesis and activator protein-1 activation.

Authors:  Victoria A Newton; Nicole M Ramocki; Brooks P Scull; James G Simmons; Kirk McNaughton; P Kay Lund
Journal:  Am J Pathol       Date:  2010-03-26       Impact factor: 4.307

4.  Cullin 5 destabilizes Cas to inhibit Src-dependent cell transformation.

Authors:  Anjali Teckchandani; George S Laszlo; Sergi Simó; Khyati Shah; Carissa Pilling; Alexander A Strait; Jonathan A Cooper
Journal:  J Cell Sci       Date:  2013-11-27       Impact factor: 5.285

5.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 6.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

7.  Socs36E attenuates STAT signaling to optimize motile cell specification in the Drosophila ovary.

Authors:  Amanda J Monahan; Michelle Starz-Gaiano
Journal:  Dev Biol       Date:  2013-04-10       Impact factor: 3.582

8.  Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression.

Authors:  Emily C Brantley; L Burton Nabors; G Yancey Gillespie; Youn-Hee Choi; Cheryl Ann Palmer; Keith Harrison; Kevin Roarty; Etty N Benveniste
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

9.  Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer.

Authors:  Walid Sasi; Wen G Jiang; Anup Sharma; Kefah Mokbel
Journal:  BMC Cancer       Date:  2010-04-30       Impact factor: 4.430

10.  SOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence.

Authors:  Frédérick A Mallette; Viviane Calabrese; Subburaj Ilangumaran; Gerardo Ferbeyre
Journal:  Aging (Albany NY)       Date:  2010-07       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.